{"id":"nurofen-plus","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibuprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Codeine phosphate acts as a weak opioid agonist at mu receptors in the central nervous system to enhance analgesia. The combination provides synergistic pain relief for moderate pain that does not respond adequately to either agent alone.","oneSentence":"Nurofen Plus combines ibuprofen (a nonsteroidal anti-inflammatory drug) with codeine phosphate (an opioid analgesic) to provide enhanced pain relief through dual analgesic and anti-inflammatory action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:38.520Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate acute pain (headache, dental pain, period pain, backache, minor injuries)"}]},"trialDetails":[{"nctId":"NCT07036861","phase":"PHASE1","title":"A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension","status":"COMPLETED","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2023-11-06","conditions":"Healthy Male and Female Subjects","enrollment":74},{"nctId":"NCT03496324","phase":"PHASE1","title":"Ibuprofen 4% (w/v) Pivotal Bioequivalence Study","status":"COMPLETED","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","startDate":"2016-02-29","conditions":"Bioequivalence of the Test Formulation","enrollment":24},{"nctId":"NCT01229449","phase":"PHASE3","title":"Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study","status":"COMPLETED","sponsor":"Reckitt Benckiser LLC","startDate":"2009-01","conditions":"Post-operative Pain","enrollment":678},{"nctId":"NCT02503085","phase":"PHASE1","title":"Ibuprofen Suspension Bioequivalence Study","status":"COMPLETED","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","startDate":"2015-06-02","conditions":"Healthy Volunteer Study","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ibuprofen/Codeine"],"phase":"phase_3","status":"active","brandName":"Nurofen Plus®","genericName":"Nurofen Plus®","companyName":"Reckitt Benckiser LLC","companyId":"reckitt-benckiser-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nurofen Plus combines ibuprofen (a nonsteroidal anti-inflammatory drug) with codeine phosphate (an opioid analgesic) to provide enhanced pain relief through dual analgesic and anti-inflammatory action. Used for Moderate acute pain (headache, dental pain, period pain, backache, minor injuries).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}